LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Kura Oncology Inc

Fechado

SetorSaúde

7.99 -1.48

Visão Geral

Variação de preço das ações

24h

Atual

Mín

7.86

Máximo

8.16

Indicadores-chave

By Trading Economics

Rendimento

-8.7M

-66M

Vendas

1.2M

15M

Margem de lucro

-432.509

Funcionários

192

EBITDA

-8M

-73M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+188.32% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

139M

686M

Abertura anterior

9.47

Fecho anterior

7.99

Sentimento de Notícias

By Acuity

50%

50%

173 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Kura Oncology Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de set. de 2025, 23:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 de set. de 2025, 22:02 UTC

Grandes Movimentos do Mercado

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 de set. de 2025, 17:01 UTC

Grandes Movimentos do Mercado

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 de set. de 2025, 17:01 UTC

Grandes Movimentos do Mercado

Tron Shares Rise After New Investment From Bravemorning

8 de set. de 2025, 16:14 UTC

Grandes Movimentos do Mercado

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 de set. de 2025, 16:13 UTC

Grandes Movimentos do Mercado

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 de set. de 2025, 23:12 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 de set. de 2025, 23:12 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de set. de 2025, 23:12 UTC

Conversa de Mercado

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 de set. de 2025, 22:56 UTC

Conversa de Mercado

Worst May Be Over for New Zealand Retailers -- Market Talk

8 de set. de 2025, 22:23 UTC

Conversa de Mercado

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 de set. de 2025, 21:51 UTC

Conversa de Mercado

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 de set. de 2025, 21:47 UTC

Grandes Movimentos do Mercado

Microsoft Signs $17.4B AI Deal With Nebius

8 de set. de 2025, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 de set. de 2025, 21:20 UTC

Aquisições, Fusões, Aquisições de Empresas

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 de set. de 2025, 21:19 UTC

Aquisições, Fusões, Aquisições de Empresas

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 de set. de 2025, 21:18 UTC

Aquisições, Fusões, Aquisições de Empresas

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 de set. de 2025, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

8 de set. de 2025, 19:33 UTC

Conversa de Mercado

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 de set. de 2025, 19:22 UTC

Conversa de Mercado

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 de set. de 2025, 19:02 UTC

Conversa de Mercado

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 de set. de 2025, 18:24 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 de set. de 2025, 18:24 UTC

Conversa de Mercado

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 de set. de 2025, 17:29 UTC

Conversa de Mercado

Mexican Inflation Seen Little Changed in August -- Market Talk

8 de set. de 2025, 16:59 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 de set. de 2025, 16:36 UTC

Conversa de Mercado

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 de set. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 de set. de 2025, 16:16 UTC

Ganhos

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 de set. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

8 de set. de 2025, 16:04 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

Comparação entre Pares

Variação de preço

Kura Oncology Inc Previsão

Preço-alvo

By TipRanks

188.32% parte superior

Previsão para 12 meses

Média 23.7 USD  188.32%

Máximo 40 USD

Mínimo 7.95 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Kura Oncology Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

13 ratings

11

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

5.575 / 6.6Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

173 / 371 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.
help-icon Live chat